A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Intepirdine (Primary)
- Indications Lewy body disease
- Focus Registrational; Therapeutic Use
- Acronyms HEADWAY; HEADWAY-DLB
- Sponsors Axovant Sciences
- 08 Jan 2018 Results presented in an Axovant Sciences media release.
- 08 Jan 2018 According to a company media release, Axovant Sciences has decided to discontinue intepirdine program based on negative results from MINDSET, HEADWAY and Gait and Balance studies.
- 08 Jan 2018 Primary endpoint (Change from baseline on Unified Parkinsons Disease Rating Scale-Part III (UPDRS-III)) has not been met, according to an Axovant Sciences media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History